2024-07-1921075.75 KB1页19
2024-07-19210580.41 KB8页18
2024-07-19210351.37 KB34页21
2024-07-192105.8 MB29页28
2024-07-192102.18 MB19页17
2024-07-192104.03 MB35页14
2024-07-192109.41 MB56页22
2024-07-1921031.57 MB136页15
2024-07-192107.33 MB52页29
2024-07-192107.1 MB112页6
2024-07-192103.58 MB35页26
2024-07-19210420.58 KB21页12
中国后循环缺血专家共识解读上海交通大学医学院附属仁济医院神经科李焰生中国后循环缺血专家共识组（按姓氏汉语拼音顺序）陈海波,陈康宁，陈晓春,程焱,董强,董绥君，冯加纯,贺茂林,胡长林,胡兴越,胡学强,季晓林,郎森阳,李焰生,刘春风，刘鸣,潘晓平，戚晓昆,汪昕,王丽娟,王柠,王少石,王伟,王维治,王伊龙，王拥军,余华峰，张朝东,张苏明,张微微,张茁,曾进胜，周盛年中国后循环缺血专家共识共识内容一．后循环缺血的认识、定义和意... 2024-07-172102.48 MB81页7
2024-07-17210962.66 KB24页23
2024-07-172101.37 MB32页5
2024-07-172101.04 MB15页14
“中国新靶点”数据分析赋能未满足临床需求药物研发王中健博士享融智云CEOhttps://www.pharnexcloud.com/目录CONTENTS01新药研发现状及热门靶点概述02深入挖掘“中国新靶点”03各适应症“中国新靶点”分析04总结https://www.pharnexcloud.com/全球新药数量分阶段统计124,521国内首家研发企业43,909国外首家研发企业80,61215,5905,0224,9266,1163,0271,413774787药物发现12,5634,1521,6155,329334临床前4604723,609II期临床1,281... 2024-07-172108.18 MB31页24
ReviewRenalDenervationinAsiaConsensusStatementoftheAsiaRenalDenervationConsortiumKazuomiKario,Byeong-KeukKim,JiroAoki,AnthonyYiu-tungWong,Ying-HsiangLee,NattawutWongpraparut,QuangNgocNguyen,WanAzmanWanAhmad,SooTeikLim,TiongKiamOng,Tzung-DauWangAbstract—TheAsiaRenalDenervationConsortiumconsensusconferenceofAsianphysiciansactivelyperformingrenaldenervation(RDN)wasrecentlyconvenedtoshareup-to-dat... 2024-07-252091.46 MB13页8
2024-07-25209366.65 KB1页7
2024-07-242091.69 MB18页25
